Modus Therapeutics participates in FS markets Investment Meeting-Live on September 23rd
On Thursday, 23 September 2021 at 5.30 pm, Modus Therapeutics AB (“Modus”) will participate in FS Markets Investerarmötet-Live (Investment Meeting-Live). Modus CEO John Öhd will present the company and discuss upcoming plans.Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition. Investor Meeting-Live is a live webcast seminar. The presentation will be followed by a question-and-answer session where you can ask